comprehensive -WSS

comprehensive

author：hotspot 2025-09-02 08:26:03 - browse：6

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Updated Covid vaccine has 54% effectiveness, new study suggests

WSS

Why Novartis is going to walk from its acquisition of MorphoSys

Why Novartis is going to walk from its acquisition of MorphoSys

The CDC's new social media misinformation war

The new shift in health care is toward less care

Unique patient identifier: Experts argue the benefits, pitfalls

Biotech incubator Curie.Bio graduates its first startup

hotspot

comprehensive

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Gene therapy for Afghan refugees’ infant will be fully covered

New air purifier tech could be key to improving indoor air quality

Surgery pushed Ben Carson to fame

Alkermes shareholders re

A single Democrat is willing to weaken Medicare negotiation power

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Amgen, Regeneron, BGI Group and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A single Democrat is willing to weaken Medicare negotiation power

hotspot

340B reform proposal comes out of Senate working group

The new shift in health care is toward less care

Excited delirium, Elijah McClain, and emergency physicians

White House calls on federal agencies to crack down on AI abuses

What’s missing from the debate over nursing home staff minimums

AstraZeneca stays mum on Medicare drug pricing negotiations

entertainment

knowledge

entertainment

entertainment